Southern Medical University, Guangzhou, China.
Pathol Res Pract. 2011 Jan 15;207(1):1-7. doi: 10.1016/j.prp.2010.08.005. Epub 2010 Nov 20.
DCIS of the breast with coexisting invasion is commonly seen, and no consensus on any biomarker capable of discriminating this subgroup has been reached yet. We retrospectively examined the receptor status and the histological grade in Chinese DCIS patients to identify any independent predictor in order to discriminate a subgroup with coexisting invasion from pure DCIS patients. A consecutive Chinese DCIS patient cohort registered at a single institution was included for ER, PR, and HER2 status, as well as for evaluation of the histological grade. Patients with invasion foci >1cm in diameter were excluded. The HER2 gene amplification status was further examined by FISH when the IHC result was HER2 (2+). Molecular subtypes were also profiled. Age, histological grade, ER, PR, and HER2 status were included in association analyses. In total, 183 patients were included. A hundred and forty patients had pure DCIS, and 43 patients had DCIS with invasion. The luminal A subtype accounted for 49.7% of all cases, the HER2-positive subtype for 27.9%, and only 10.4% and 12.0% represented the luminal B and basal-like subtypes, respectively. Univariate analyses showed that histological Grade 2, Grade 3, and HER2-positive status were associated with DCIS with invasion, odds ratios 5.1 (P = 0.017), 5.2 (P = 0.01) and 3.34 (P = 0.001), respectively. However, only the HER2-positive status was of statistical significance in the multivariate logistic regression analyses after adjustment for other markers, odds ratio 3.8 (95%CI 1.4-10, P = 0.008). The 43 cases with invasion were further stratified into extensive or small DCIS components according to the percentage of DCIS to total tumor area using 25% as the cutoff point. Multinomial logistic regression with pure DCIS cases as reference showed that the HER2-positive status was associated only with the group showing an extensive DCIS component, odds ratio 6.2 (95%CI 1.8-21, P = 0.003), but not with the group having a small DCIS component. Our study demonstrates that HER2-positive status is an independent predictor for DCIS, with invasion presenting an extensive DCIS component, and favors the hypothesis that HER2 overexpression or gene amplification is involved in the transition from DCIS to invasive disease.
乳腺伴浸润性的 DCIS 较为常见,但目前尚未达成任何能够区分该亚组的生物标志物的共识。我们回顾性分析了中国 DCIS 患者的受体状态和组织学分级,以确定任何独立的预测因子,以便将伴浸润性的亚组与单纯 DCIS 患者区分开来。在一个机构注册的连续中国 DCIS 患者队列中,我们对 ER、PR 和 HER2 状态以及组织学分级进行了评估。排除了直径大于 1cm 的浸润灶患者。当 IHC 结果为 HER2(2+)时,进一步通过 FISH 检查 HER2 基因扩增状态。将年龄、组织学分级、ER、PR 和 HER2 状态纳入关联分析。共有 183 例患者入选。140 例患者为单纯 DCIS,43 例患者为 DCIS 伴浸润。所有病例中,腔 A 型占 49.7%,HER2 阳性型占 27.9%,仅 10.4%和 12.0%分别代表腔 B 型和基底样型。单因素分析显示,组织学分级 2 级、3 级和 HER2 阳性与 DCIS 伴浸润相关,比值比分别为 5.1(P = 0.017)、5.2(P = 0.01)和 3.34(P = 0.001)。然而,在调整其他标志物后,多变量逻辑回归分析仅显示 HER2 阳性状态具有统计学意义,比值比为 3.8(95%CI 1.4-10,P = 0.008)。根据 DCIS 占肿瘤总面积的百分比(以 25%为截断点),43 例伴浸润的患者进一步分为广泛或小的 DCIS 成分亚组。以单纯 DCIS 病例为参照的多项逻辑回归显示,HER2 阳性状态仅与表现为广泛 DCIS 成分的组相关,比值比为 6.2(95%CI 1.8-21,P = 0.003),而与表现为小 DCIS 成分的组无关。我们的研究表明,HER2 阳性状态是 DCIS 伴浸润的独立预测因子,伴广泛的 DCIS 成分,并支持 HER2 过表达或基因扩增参与从 DCIS 向浸润性疾病转变的假说。